Keysight Technologies enters the final week of September riding its strongest monthly stretch in some time — up 11% on the week and nearly 10% over the past month to close at $347.32 — and the interesting tension here is that neither shorts nor options traders are pushing back against the move.
The borrow market offers no resistance to speak of. Availability is essentially unlimited, with over 168 million shares free to lend against a short position of just 1.7% of free float. Short interest has actually slipped nearly 9% over the past month, continuing a steady decline from late-August levels when roughly 3.3 million shares were short. Cost to borrow is minimal at 0.34%, down 12% on the week. Nothing in the lending market points to conviction from the bear side. The ORTEX short score of 30.3 confirms this — well below levels that signal crowded positioning — and has been flat across the past two weeks, showing no attempt by shorts to rebuild as the stock rallied. Options traders are similarly unbothered. The put/call ratio is running just below its 20-day average at 0.62, slightly below the norm of 0.63, and the z-score of -0.48 sits almost exactly neutral. Neither camp is hedging against this rally.
The bull case is anchored in fundamentals. Street targets, while set in mid-August after Q3 earnings, are clustered between $400 and $440 — a meaningful premium to the current price of $347. JP Morgan and Morgan Stanley both held Overweight ratings and lifted targets to $425 after the print, while UBS and Susquehanna pushed to $440. Barclays moved the most aggressively, lifting from $387 to $429. The lone dissenter at Hold, Truist Securities, also raised its target — to $400 from $376. With the consensus barely reflecting sell-side skepticism, the implied return potential from analyst targets is still substantial even after an 11% week. On valuation, the trailing P/E has expanded to around 26x over the past month, and the price-to-book has climbed alongside it. Neither is stretched by tech-adjacent standards, but both have re-rated noticeably. EPS momentum ranks in the 93rd percentile on a 30-day basis, the highest in the factor profile, and the short score rank of 76 reflects that bearish pressure on this stock is low relative to peers.
Two institutional flows stand out this quarter. BlackRock added 1.47 million shares in the most recent period, bringing its stake to nearly 12% of shares outstanding — the largest single holder by a wide margin. FMR (Fidelity) added almost a million shares, raising its position to around 1.1% of the float. On the flip side, T. Rowe Price's most recent Schedule 13G/A, filed in August, showed its reportable stake dropping from 8.7% to 5.6% — a reduction of roughly 3 percentage points that has been playing out over multiple filings. T. Rowe's trimming is worth noting as a counterweight to the otherwise constructive institutional flow, though the aggregate direction of ownership change remains net positive. On the insider side, the CFO sold 2,000 shares at $340.79 on September 21 — a discretionary sale, not under a 10b5-1 plan — worth roughly $682,000. That follows a similar-sized open-market sale from SVP Estrada in early September. Neither trade is large relative to the company's size, but discretionary selling into a rally is worth flagging.
The last earnings print, delivered August 18, saw the stock drop just over 11% in a single session and give back a similar amount across the following five days — a reminder that the market's expectations going into the next report on November 24 will matter more than the absolute numbers. With the stock now trading nearly 9% above where it stood the day before that print, and consensus targets clustered in the low-to-mid $400s, the setup heading into Q4 results is one to watch: how much of the Street's optimism the stock can hold at current levels, and whether insider selling into this strength broadens ahead of November.
See the live data behind this article on ORTEX.
Open KEYS on ORTEX →ORTEX Market Intelligence content is generated by AI from a snapshot of ORTEX's proprietary data. Content is informational only and does not constitute investment advice.
